127 related articles for article (PubMed ID: 38669912)
1. Coordination environment dependence of anticancer activity in cyclometalated bismuth(III) complexes with C,O-chelating ligands.
Lei J; Liu Y; Yin M; Li S; Wang Z; Chen Y
J Inorg Biochem; 2024 Jul; 256():112571. PubMed ID: 38669912
[TBL] [Abstract][Full Text] [Related]
2. Vanadocene complexes bearing N,N'-chelating ligands: Synthesis, structures and in vitro cytotoxic studies on the A549 lung adenocarcinoma cell line.
Melounková L; Machálková A; Havelek R; Honzíček J; Řezáčová M; Císařová I; Peterová E; Vinklárek J
J Inorg Biochem; 2019 Jun; 195():182-193. PubMed ID: 30959320
[TBL] [Abstract][Full Text] [Related]
3. Investigation into antiproliferative activity and apoptosis mechanism of new arene Ru(ii) carbazole-based hydrazone complexes.
Sathiya Kamatchi T; Mohamed Subarkhan MK; Ramesh R; Wang H; Małecki JG
Dalton Trans; 2020 Aug; 49(32):11385-11395. PubMed ID: 32776042
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity and apoptotic activity of novel organobismuth(V) and organoantimony(V) complexes in different cancer cell lines.
Islam A; Rodrigues BL; Marzano IM; Perreira-Maia EC; Dittz D; Paz Lopes MT; Ishfaq M; Frézard F; Demicheli C
Eur J Med Chem; 2016 Feb; 109():254-67. PubMed ID: 26774931
[TBL] [Abstract][Full Text] [Related]
5. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
6. Promoting the Anticancer Activity with Multidentate Furan-2-Carboxamide Functionalized Aroyl Thiourea Chelation in Binuclear Half-Sandwich Ruthenium(II) Complexes.
Thangavel SK; Mohamed Kasim MS; Rengan R
Inorg Chem; 2024 Apr; 63(16):7520-7539. PubMed ID: 38590210
[TBL] [Abstract][Full Text] [Related]
7. May iron(III) complexes containing phenanthroline derivatives as ligands be prospective anticancer agents?
Matos CP; Adiguzel Z; Yildizhan Y; Cevatemre B; Onder TB; Cevik O; Nunes P; Ferreira LP; Carvalho MD; Campos DL; Pavan FR; Pessoa JC; Garcia MH; Tomaz AI; Correia I; Acilan C
Eur J Med Chem; 2019 Aug; 176():492-512. PubMed ID: 31132480
[TBL] [Abstract][Full Text] [Related]
8. Studies on the cytotoxicity and anticancer performance of heterocyclic hypervalent organobismuth(III) compounds.
Liu YP; Lei J; Tang LW; Peng Y; Au CT; Chen Y; Yin SF
Eur J Med Chem; 2017 Oct; 139():826-835. PubMed ID: 28865278
[TBL] [Abstract][Full Text] [Related]
9. Mitochondria-targeted neutral and cationic iridium(III) anticancer complexes chelating simple hybrid sp
Li P; Guo L; Li J; Yang Z; Fu H; Lai K; Dong H; Fan C; Liu Z
Dalton Trans; 2024 Jan; 53(5):1977-1988. PubMed ID: 38205595
[TBL] [Abstract][Full Text] [Related]
10. High in vitro and in vivo antitumor activities of Ln(III) complexes with mixed 5,7-dichloro-2-methyl-8-quinolinol and 4,4'-dimethyl-2,2'-bipyridyl chelating ligands.
Meng T; Qin QP; Chen ZL; Zou HH; Wang K; Liang FP
Eur J Med Chem; 2019 May; 169():103-110. PubMed ID: 30870791
[TBL] [Abstract][Full Text] [Related]
11. Recent Research Trends on Bismuth Compounds in Cancer Chemoand Radiotherapy.
Kowalik M; Masternak J; Barszcz B
Curr Med Chem; 2019; 26(4):729-759. PubMed ID: 28971764
[TBL] [Abstract][Full Text] [Related]
12. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
[TBL] [Abstract][Full Text] [Related]
13. New Variations on the Theme of Gold(III) C
Carboni S; Zucca A; Stoccoro S; Maiore L; Arca M; Ortu F; Artner C; Keppler BK; Meier-Menches SM; Casini A; Cinellu MA
Inorg Chem; 2018 Dec; 57(23):14852-14865. PubMed ID: 30457328
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, X-ray structure and cytotoxic effect of nickel(II) complexes with pyrazole ligands.
Sobiesiak M; Lorenz IP; Mayer P; Woźniczka M; Kufelnicki A; Krajewska U; Rozalski M; Budzisz E
Eur J Med Chem; 2011 Dec; 46(12):5917-26. PubMed ID: 22047642
[TBL] [Abstract][Full Text] [Related]
15. One dodecahedral bismuth(III) complex derived from 2-acetylpyridine N(4)-pyridylthiosemicarbazone: synthesis, crystal structure and biological evaluation.
Li M; Lu Y; Yang M; Li Y; Zhang L; Xie S
Dalton Trans; 2012 Nov; 41(41):12882-7. PubMed ID: 22986888
[TBL] [Abstract][Full Text] [Related]
16. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents.
Gaspari APS; da Silva RS; Carneiro ZA; de Carvalho MR; Carvalho I; Pernomian L; Ferreira LP; Ramos LCB; de Souza GA; Formiga ALB
Anticancer Agents Med Chem; 2021; 21(12):1602-1611. PubMed ID: 33081686
[TBL] [Abstract][Full Text] [Related]
17. A bismuth diethyldithiocarbamate compound induced apoptosis via mitochondria-dependent pathway and suppressed invasion in MCF-7 breast cancer cells.
Chan PF; Ang KP; Hamid RA
Biometals; 2021 Apr; 34(2):365-391. PubMed ID: 33555494
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyquinoline derived vanadium(IV and V) and copper(II) complexes as potential anti-tuberculosis and anti-tumor agents.
Correia I; Adão P; Roy S; Wahba M; Matos C; Maurya MR; Marques F; Pavan FR; Leite CQF; Avecilla F; Costa Pessoa J
J Inorg Biochem; 2014 Dec; 141():83-93. PubMed ID: 25226436
[TBL] [Abstract][Full Text] [Related]
19. Anticancer potential of (pentamethylcyclopentadienyl)chloridoiridium(III) complexes bearing κP and κP,κS-coordinated Ph2 PCH2 CH2 CH2 S(O)x Ph (x=0-2) ligands.
Ludwig G; Ranđelović I; Maksimović-Ivanić D; Mijatović S; Bulatović MZ; Miljković D; Korb M; Lang H; Steinborn D; Kaluđerović GN
ChemMedChem; 2014 Jul; 9(7):1586-93. PubMed ID: 24470190
[TBL] [Abstract][Full Text] [Related]
20. Cyclometalated Ru(II)-isoquinoline complexes overcome cisplatin resistance of A549/DDP cells by downregulation of Nrf2 via Akt/GSK-3β/Fyn pathway.
Chen L; Wang J; Cai X; Chen S; Zhang J; Li B; Chen W; Guo X; Luo H; Chen J
Bioorg Chem; 2022 Feb; 119():105516. PubMed ID: 34856444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
